Spectrofluorimetric analysis of ticagrelor in pharmaceutical formulations and spiked human plasma using 1-dimethylaminonaphthalene-5-sulphonyl chloride reagent

A sensitive method is presented for the determination of the ticagrelor (TCG) in human plasma andpharmaceutical preparations using 5-(dimethylamino)naphthalene-1-sulfonyl chloride (dansyl chloride). Ticagrelorcontains a secondary amino group which reacts with dansyl chloride in the presence of 0.5 M sodium bicarbonate (pH10) to yield a highly fluorescent derivative that is measured at 445 nm after excitation at 340 nm. Different experimentalparameters affecting the fluorescence intensities were carefully studied and optimized. The proposed method was alsovalidated according to ICH guidelines. The fluorescence concentration plot was rectilinear over the range of 20.0–200.0 ng mL−1, with a coefficient of determination of 0.9999 with a limit of detection (LOD) of 0.14 ng mL−1 and the limitof quantitation (LOQ) of 0.46 ng mL−1. The proposed method was applied successfully to the analysis of TCG in spikedhuman plasma and pharmaceutical dosage forms with good accuracy and precision.

PDF

___

[1] van Giezen JJ, Nilsson L, Berntsson P, Wissing BM, Giordanetto F, Tomlinson W, Greasley PJ. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and PA. J Thromb Haemost. 2009; 7(9): 1556–1565. [CrossRef]
[2] Nylander S, Schulz R. Effects of P2Y12 receptor antagonists beyond platelet inhibition—comparison of ticagrelor with thienopyridines. Br J Pharmacol. 2016; 173(7): 1163–1178. [CrossRef]
[3] Husted S, van Giezen JJ. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther. 2009; 27(4): 259–274. [CrossRef]
[4] Butler K, Teng R. Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Br J Clin Pharmacol. 2010; 70(1): 65–77. [CrossRef]
[5] Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006; 27(9): 1038–1047. [CrossRef]
[6] Zhou D, Andersson TB, Grimm SW. In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics. Drug Metab Dispos. 2011; 39(4): 703–710. [CrossRef]
[7] Ambasana M, Kapuriya N, Faldu N, Ladva K.Development and validation of a UV spectrophotometric method for the determination of ticagrelor in bulk form. Der Pharmacia Lett. 2014; 4: 237-240.
[8] Kalyani L, Lakshmana Rao A.A Validated Stability Indicating HPLC Method for determination of ticagrelor in bulk and its formulation. Int J Pharmacy. 2013; 3:634-642.
[9] Caren G, Pereira RL, Mendez ASL, Garcia CV. Determination of the New Antiplatelet Agent Ticagrelor in tablets by stability-indicating HPLC method. Current Pharmaceut Anal. 2014; 10(4): 279-283. [CrossRef]
[10] Ambasana A, Kapuriya, NP, Mangtani KM, Ladva KD. An improved assay method for the estimation of ticagrelor hydrochloride by reverse phase liquid chromatography. Int J Pharm Sci Res. 2016; 7(5): 2009-2014. [CrossRef]
[11] Sillén H, Cook M, Davis P. Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2010; 878(25): 2299-2306. [CrossRef]
[12] Sillén H, Cook M, Davis P. Determination of unbound ticagrelor and its active metabolite (AR-C124910-XX) in human plasma by equilibrium dialysis and LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2011;23:2315-2322. [CrossRef]
[13] Zhong W, Wang X, Tang L, Mai L, Chen XP, He G, Zheng Z, Zhong S. Simultaneous Determination of Ticagrelor and its metabolites in human plasma and urine using liquid chromatography-tandem mass Spectrometry. J Anal Toxicol. 2016; 40(6): 445-453. [CrossRef]
[14] Sandinge AS, Janefeldt A, Pehrsson S, Nylander S. Quantification of unbound concentration of ticagrelor in plasma as a proof of mechanism biomarker of the reversal agent, MEDI2452. PLoS One. 2018; 13(7): e0201202. [CrossRef]
[15] Chae SI, Yoo HJ, Lee SY, Chung EK, Shim WS, Lee KT. Development and Validation of Simple LC-MS-MS Assay for the Quantitative Determination of Ticagrelor in Human Plasma: its Application to a Bioequivalence Study. J Chromatogr Sci. 2019; 57(4): 331-338. [CrossRef]
[16] Hornyak I, Kozma L, Lapat A, Tovari I.Spectrofluorimetric determination of diethazine and promethazine in pharmaceutical preparations. Biomed Chromatogr. 1997; 11(2): 99-101. [CrossRef]
[17] Danielak D, Gorzycka P, Kruszyna Ł, Karaźniewicz-Łada M, Główka F. Development of an LC-MS/MS method for simultaneous determination of ticagrelor and its active metabolite during concomitant treatment with atorvastatin. J Chromatogr B Analyt Technol Biomed Life Sci. 2019; 1105: 113-119. [CrossRef]
[18] Kelemen H, Hancu G, Papp LA. Analytical methodologies for the determination of ticagrelor. Biomed Chromatogr. 2019:e4528. [CrossRef]
[19] Rizk M, Belal F, Ibrahim F. Ahmed S, el-Enany N. Spectrofluorimetric analysis of certain 4-quinolone in pharmaceuticals and biological fluids. Pharm Acta Helv. 2000; 74(4): 371-377. [CrossRef]
[20] Weber G. Polarization of the fluorescence of macromolecules. 2. Fluorescent conjugates of ovalbumin and bovine serum albumin. Biochem J. 1952; 51:155-167. [CrossRef]
[21] El-Enany N, Belal F, Rizk M. Spectrofluorimetric determination of oxamniquine in dosage forms and spiked human plasma through derivatization with 1 dimethylaminonaphthalene-5-sulphonyl chloride. J Fluoresc. 2008; 18(2): 349- 355. [CrossRef]
[22] Garcia SF, Cruces BC. Determination of the insecticide promecarb by fluorogenic labeling with dansyl chloride. Analyst. 1991; 116: 851-858.
[23] Fattah A, El Sayed L, Taghreed M A, Elham Anwer T. Spectrofluorimetric determination of carvedilol in dosage form and spiked human plasma through derivatization with 1-dimethylamino-naphthalene-5-sulphonyl chloride. Chem Ind Chem Eng Q. 2010; 16: 31-38. [CrossRef]
[24] Penzes LP, Oertel GW.Determination of steroids by densitometry of derivatives. II. Direct fluorometry of dansyl estrogens. J Chromatogr. 1970; 51: 325-327.
[25] Robert W. Roos, High pressure liquid chromatographic analysis of estrogens in pharmaceuticals by measurement of their dansyl derivatives. J Pharm Sci. 2006; 67(12): 1735-1739. [CrossRef]
[26] Seiler N, Wiechmann M, in Niedeswieses A,Pataki, G. Editors, Progress in Thin Layer Chromatography and Related Methods, Ann Arbor-Humphrey Science Publishers, Ann Arbor, MI, 1970, p. 94.
[27] Tekkeli ŞEK Spectrofluorimetric Method for the Determination of Tolterodine in human plasma and pharmaceutical preparations by derivatization with dansyl chloride. Bezmialem Sci. 2017; 5: 50-55. [CrossRef]
[28] Wang X, Liang Y, Wang Y, Fan M, Sun Y, Liu J, Zhang N. Simultaneous determination of 10 kinds of biogenic amines in rat plasma using high-performance liquid chromatography coupled with fluorescence detection. Biomed Chromatogr. 2018; 32(6): e 4211. [CrossRef]
[29] Job P. Formation and Stability of Inorganic Complexes in Solution. Anal Chim. 1928; 9: 113-203.
[30] International Conference on HarmonizationTopic Q2 (R1) Validation of Analytical Procedures: Text and Methodology (2005).
[31] Jeon HS, Kim MJ, Choi HY, Kim YH, Kim EH, Kim AR, Park HJ, Bae KS, Lim HS. Pharmacokinetics and pharmacodynamics of ticagrelor and prasugrel in healthy male Korean volunteers. Clin Ther. 2015; 37(3): 563-573. [CrossRef]